2. Metabolic Enzyme/Protease
  3. Endogenous Metabolite
  4. L-Tartaric acid

L-Tartaric acid  (Synonyms: L-(+)-Tartaric acid)

Cat. No.: HY-Y0293 Purity: ≥98.0%
COA Handling Instructions

Molarity Calculator

L-tartaric acid (L-(+) -tartaric acid) is an orally active weak organic acid that can be isolated from grapes. L-Tartaric acid has vasodilatory and antihypertensive effects. L-Tartaric acid can be used as flavorings and antioxidants in a range of foods and beverages. L-Tartaric acid can be used in laser frequency doubling and optical limiting applications.

For research use only. We do not sell to patients.

L-Tartaric acid Chemical Structure

L-Tartaric acid Chemical Structure

CAS No. : 87-69-4

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 33 In-stock
Solution
10 mM * 1 mL in DMSO USD 33 In-stock
Solid
100 mg USD 30 In-stock
500 mg USD 50 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of L-Tartaric acid:

L-Tartaric acid Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

L-tartaric acid (L-(+) -tartaric acid) is an orally active weak organic acid that can be isolated from grapes. L-Tartaric acid has vasodilatory and antihypertensive effects. L-Tartaric acid can be used as flavorings and antioxidants in a range of foods and beverages. L-Tartaric acid can be used in laser frequency doubling and optical limiting applications[1][2][3][4].

IC50 & Target

Microbial Metabolite

 

Human Endogenous Metabolite

 

In Vitro

L-Tartaric acid (1.66-6.64 mM) significantly reduces NEP and KCL-induced aortic ring vasoconstriction with EC50 values of 4.119 mM and 4.00 mM, respectively[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

L-Tartaric acid Related Antibodies
In Vivo

L-Tartaric acid (80-240 mg/kg; P.O.; Single dose) reduces blood pressure in hypertensive mice induced by L-NAME (60 mg/kg) [3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Hypertensive Wistar rat model[3]
Dosage: 80 mg/kg, 240 mg/kg
Administration: Oral gavage (p.o.); Single dose. After L-NAME treatment (60.mg/kg; p.o.)
Result: Reduced systolic blood pressure (SABP) and mild blood pressure (mid-BP) in rats at a dose of 240mg/kg, but had no effect on mean artery pressure, diastolic blood pressure, pulse pressure level, and heart rate.
Molecular Weight

150.09

Formula

C4H6O6
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(O)[C@H](O)[C@@H](O)C(O)=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (666.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 6.6627 mL 33.3133 mL 66.6267 mL
5 mM 1.3325 mL 6.6627 mL 13.3253 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (16.66 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (16.66 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: ≥98.0%

COA (247 KB) HNMR (128 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 6.6627 mL 33.3133 mL 66.6267 mL 166.5667 mL
5 mM 1.3325 mL 6.6627 mL 13.3253 mL 33.3133 mL
10 mM 0.6663 mL 3.3313 mL 6.6627 mL 16.6567 mL
15 mM 0.4442 mL 2.2209 mL 4.4418 mL 11.1044 mL
20 mM 0.3331 mL 1.6657 mL 3.3313 mL 8.3283 mL
25 mM 0.2665 mL 1.3325 mL 2.6651 mL 6.6627 mL
30 mM 0.2221 mL 1.1104 mL 2.2209 mL 5.5522 mL
40 mM 0.1666 mL 0.8328 mL 1.6657 mL 4.1642 mL
50 mM 0.1333 mL 0.6663 mL 1.3325 mL 3.3313 mL
60 mM 0.1110 mL 0.5552 mL 1.1104 mL 2.7761 mL
80 mM 0.0833 mL 0.4164 mL 0.8328 mL 2.0821 mL
100 mM 0.0666 mL 0.3331 mL 0.6663 mL 1.6657 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

L-Tartaric acid Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

L-Tartaric acid87-69-4L-(+)-Tartaric acidEndogenous Metabolitevasodilatationhypertensionfood additivesantioxidantcondimentlaser frequency doublingoptical limitingInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
L-Tartaric acid
Cat. No.:
HY-Y0293
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.